Evaluate the status of the immune system
Immunoprofiling for drug development
Cell and gene therapies require monitoring of immune system activation. Bioanalysis, such as biodistribution, shedding, and pharmacokinetics, cannot be trusted if the immune response degrades the drug. In clinical trials, the therapeutic effect can be lost, or activation of the immune system can result in serious adverse effects. We have the tools to monitor the immune response.
Early and adaptive immune activation
Precise immune response measurements
The immune system protects us from foreign microorganisms, but in the case of cell and gene therapies, it’s crucial for the introduced foreign nucleic acids to have minimal impact on the immune response. We measure both the immediate innate immune response and the adaptive immune response using qPCR, dPCR, NGS, and Olink’s protein profiling.
Effortless cytokine monitoring
Using Olink’s Target 48 Cytokine panels, the nonspecific, rapid innate immune response can be easily monitored. These panels, designed for use with mouse or human samples, provide absolute quantification of key cytokines using only microliters of blood or plasma, allowing for precise measurement and comparison between samples. We perform the analysis with minimal hands-on time, with all pipetting done by robots.
TCR and BCR repertoire sequencing
With optimized, high-throughput sequencing of T-cell receptors and B-cell receptors, we monitor the adaptive immune system. This allows us to evaluate how a drug affects the immune system and to track treatment efficacy through the persistence and expansion of engineered T-cells in CAR-T treatments.
For custom immune strategies
Immune biomarkers
For specific immune biomarkers, we custom design and validate the extraction and qPCR/dPCR assays to quantify gene expression in the biological samples of your choice, according to your assay requirements.
Protein profiling
Olink provides several immunological panels where essential immuno proteins are quantified, either absolutely or relatively, depending on the chosen panel. All panels share excellent specificity due to antibody-based detection and outstanding sensitivity with qPCR or NGS readouts. Additionally, they are highly multiplexed, quantifying hundreds of proteins per microliter of blood or plasma.
Gene expression profiles
Using transcriptomic approaches, we monitor the immunological pathways activated in a sample. We extract RNA of the required quality for transcriptomics from both fresh samples and FFPE. We utilize most commercially available kits for transcriptomics, perform quality control on the data, and assist with the analysis of up- and down-regulation.
TCR/BCR sequencing
We use Cellecta’s DriverMap DNA or RNA high-throughput sequencing workflow to assess the clonal expansion of T-cells and B-cells and their transcripts, respectively. This method is highly sensitive and can detect low-frequency, rare TCR and BCR clonotypes from low-input samples.
T-cell cytotoxicity assays A T-cell cytotoxicity assay, also known as a CD8+ T-cell cytotoxicity assay, measures the ability of cytotoxic T lymphocytes to kill target cells. In drug discovery, this assay helps us understand the immune-modulating actions of new therapeutics
The Olink Target 48 panels provide both absolute and relative quantification. These panels include cytokines and other immune-related proteins, making them ideal for monitoring immune responses. They are perfect for assessing desired immune reactions in vaccines and CAR-T therapies, as
Immunosequencing entails the high-throughput sequencing of T-cell (TCR) and B-cell receptors (BCR), offering invaluable insights into the immune response within CAR-T therapies. Download the blog as PDF. T-cell malignancies following CAR-T therapy There is a potential risk of secondary cancers
contact
Let's explore how we can support your drug development program.
General Biodistribution Page
"*" indicates required fields
